{"id":327564,"date":"2026-10-27T09:53:09","date_gmt":"2026-10-27T04:23:09","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=327564"},"modified":"2026-10-27T09:53:09","modified_gmt":"2026-10-27T04:23:09","slug":"midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/","title":{"rendered":"4 Midcap Steady Revenue Growth Stocks to Watch for Future Multibagger Potential: Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Max Healthcare Rs 835. Mazagon Dock Rs 1,875. Fortis Healthcare Rs 734.70. Dr Lal PathLabs Rs 1,855.60. Market caps from Rs 31,620 crore to Rs 85,241 crore. Data as of 26 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs are the 4 picks in this steady revenue growth stocks watchlist, with market caps between Rs 31,620 crore and Rs 85,241 crore. Max Healthcare stands out for the largest market cap at Rs 85,241 crore, while Mazagon Dock offers the highest return on equity at 26.48%. PE ratios run from 28.99 to 58.50, so compare each one with its industry PE before investing. All figures are as of 26 October 2026.<\/p>\n<\/p><\/div>\n<p>Steady revenue growth stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs meet that test, with market caps from Rs 31,620 crore to Rs 85,241 crore and Max Healthcare offering the largest market cap at Rs 85,241 crore. Each of these companies has a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and FY26 revenue growth between 10 and 20 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.<\/p>\n<p>This list covers companies with a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and FY26 revenue growth between 10 and 20 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap between Rs 30,000 crore and Rs 1 lakh crore. Investors screening steady revenue growth stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 26 October 2026 and are drawn from NSE and BSE data and company filings.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=steady-revenue-growth-stocks\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#What_Are_Steady_Revenue_Growth_Stocks_and_Why_Do_They_Attract_Multibagger_Interest\" title=\"What Are Steady Revenue Growth Stocks and Why Do They Attract Multibagger Interest?\">What Are Steady Revenue Growth Stocks and Why Do They Attract Multibagger Interest?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#Steady_Revenue_Growth_Stocks_at_a_Glance_Price_Market_Cap_PE_and_ROE\" title=\"Steady Revenue Growth Stocks at a Glance: Price, Market Cap, PE and ROE\">Steady Revenue Growth Stocks at a Glance: Price, Market Cap, PE and ROE<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#Max_Healthcare_2426_Profit_CAGR_Since_FY22\" title=\"Max Healthcare: 24.26% Profit CAGR Since FY22\">Max Healthcare: 24.26% Profit CAGR Since FY22<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#Mazagon_Dock_4401_Profit_CAGR_Since_FY22\" title=\"Mazagon Dock: 44.01% Profit CAGR Since FY22\">Mazagon Dock: 44.01% Profit CAGR Since FY22<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#Fortis_Healthcare_Five-Year_Gain_of_24147\" title=\"Fortis Healthcare: Five-Year Gain of 241.47%\">Fortis Healthcare: Five-Year Gain of 241.47%<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#Dr_Lal_PathLabs_Return_on_Equity_of_2013\" title=\"Dr Lal PathLabs: Return on Equity of 20.13%\">Dr Lal PathLabs: Return on Equity of 20.13%<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#Steady_Revenue_Growth_Stocks_Financial_Comparison_on_Growth_and_Margins\" title=\"Steady Revenue Growth Stocks: Financial Comparison on Growth and Margins\">Steady Revenue Growth Stocks: Financial Comparison on Growth and Margins<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#Institutional_Holding_in_Max_Healthcare_Mazagon_Dock_Fortis_Healthcare_and_Dr_Lal_PathLabs\" title=\"Institutional Holding in Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs\">Institutional Holding in Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#Risks_to_Weigh_in_Steady_Revenue_Growth_Stocks\" title=\"Risks to Weigh in Steady Revenue Growth Stocks\">Risks to Weigh in Steady Revenue Growth Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#How_to_Choose_Between_Steady_Revenue_Growth_Stocks\" title=\"How to Choose Between Steady Revenue Growth Stocks\">How to Choose Between Steady Revenue Growth Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#Frequently_Asked_Questions_on_Steady_Revenue_Growth_Stocks_to_Watch\" title=\"Frequently Asked Questions on Steady Revenue Growth Stocks to Watch\">Frequently Asked Questions on Steady Revenue Growth Stocks to Watch<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#Which_are_the_best_steady_revenue_growth_stocks_to_watch_for_multibagger_potential\" title=\"Which are the best steady revenue growth stocks to watch for multibagger potential?\">Which are the best steady revenue growth stocks to watch for multibagger potential?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#Is_Mazagon_Dock_a_good_stock_for_long-term_investors\" title=\"Is Mazagon Dock a good stock for long-term investors?\">Is Mazagon Dock a good stock for long-term investors?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#Can_Max_Healthcare_become_a_multibagger_from_here\" title=\"Can Max Healthcare become a multibagger from here?\">Can Max Healthcare become a multibagger from here?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#What_is_the_market_cap_of_Max_Healthcare_Mazagon_Dock_Fortis_Healthcare_and_Dr_Lal_PathLabs\" title=\"What is the market cap of Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs?\">What is the market cap of Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#What_are_the_risks_of_investing_in_steady_revenue_growth_stocks\" title=\"What are the risks of investing in steady revenue growth stocks?\">What are the risks of investing in steady revenue growth stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#Is_Mazagon_Dock_trading_below_its_industry_PE\" title=\"Is Mazagon Dock trading below its industry PE?\">Is Mazagon Dock trading below its industry PE?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/midcap-steady-revenue-growth-stocks-to-watch-multibagger-potential\/#How_much_do_institutions_hold_in_Max_Healthcare_Mazagon_Dock_Fortis_Healthcare_and_Dr_Lal_PathLabs\" title=\"How much do institutions hold in Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs?\">How much do institutions hold in Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Steady_Revenue_Growth_Stocks_and_Why_Do_They_Attract_Multibagger_Interest\"><\/span><strong>What Are Steady Revenue Growth Stocks and Why Do They Attract Multibagger Interest?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Steady revenue growth stocks are shares of mid sized companies whose sales grew by 10 to 20 per cent in FY26, a steady pace that large and mid sized businesses can sustain year after year. The four here cover hospitals, shipbuilding and diagnostics.<\/p>\n<p>Growth in the teens is easier to sustain than a sudden spike, and it usually reflects broad demand rather than a one-off. For steady revenue growth stocks, both FY26 and the latest quarter showed growth. Whichever way you read steady revenue growth stocks, the common thread is rising profit backed by complete financial data. A sensible way to study steady revenue growth stocks is to look at profit growth, returns and valuation side by side. Below, each of steady revenue growth stocks gets its own breakdown of growth, returns and valuation. Treat steady revenue growth stocks as a research list, since share prices and rankings change with every earnings season.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Steady_Revenue_Growth_Stocks_at_a_Glance_Price_Market_Cap_PE_and_ROE\"><\/span><strong>Steady Revenue Growth Stocks at a Glance: Price, Market Cap, PE and ROE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Prices are closing prices as of 26 October 2026. Mazagon Dock combines the lowest PE of the group, 28.99, with the highest return on equity, 26.48%.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">PE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Industry PE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">ROE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Debt to Equity<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">52-Week Range (Rs)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/maxhealth\/max-healthcare-institute-ltd-share-price-today\">Max Healthcare Institute<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">835<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">85,241<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">58.50<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">60.75<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">13.42%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.32<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">815.00 to 1,221.90<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/mazdock\/mazagon-dock-shipbuilders-ltd-share-price-today\">Mazagon Dock Shipbuilders<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,875<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">82,736<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">28.99<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">48.92<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">26.48%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.05<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,860.00 to 2,881.80<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/fortis\/fortis-healthcare-ltd-share-price-today\">Fortis Healthcare<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">734.70<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">55,926<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">52.24<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">60.75<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">10.53%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.35<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">565.00 to 757.40<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/lalpathlab\/dr-lal-pathlabs-ltd-share-price-today\">Dr Lal PathLabs<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,855.60<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">31,620<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">57.88<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">60.75<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">20.13%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.08<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,272.60 to 2,038.60<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Max_Healthcare_2426_Profit_CAGR_Since_FY22\"><\/span><strong>Max Healthcare: 24.26% Profit CAGR Since FY22<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Max Healthcare Institute runs a network of multi-speciality hospitals in Delhi NCR, Mumbai and other cities. It reported FY26 revenue of Rs 8,536.07 crore, up 18.82% year on year, and net profit of Rs 1,442.41 crore, up 34.07%. Net profit has compounded at 24.26% a year since FY22, while revenue has grown 20.42% a year. Operating margin was 28.15% in FY26. The debt-to-equity ratio is 0.32.<\/p>\n<p>In the June 2026 quarter, revenue rose 16.60% to Rs 2,406.69 crore and net profit grew 4.87% to Rs 322.96 crore. The share price has gained 149.91% over five years. Domestic institutions raised their holding from 17.42% in June 2025 to 29.96% in June 2026. The stock trades at a PE of 58.50 against an industry PE of 60.75, below the sector average, with a return on equity of 13.42%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Mazagon_Dock_4401_Profit_CAGR_Since_FY22\"><\/span><strong>Mazagon Dock: 44.01% Profit CAGR Since FY22<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Mazagon Dock Shipbuilders builds warships and submarines for the Indian Navy and is a key defence shipyard. It reported FY26 revenue of Rs 14,145.71 crore, up 12.77% year on year, and net profit of Rs 2,421.88 crore, up 6.35%. Net profit has compounded at 44.01% a year since FY22, while revenue has grown 23.18% a year. Operating margin was 26.20% in FY26. The debt-to-equity ratio is 0.05, which keeps interest costs low.<\/p>\n<p>The stock trades at a PE of 28.99 against an industry PE of 48.92, below the sector average, with a return on equity of 26.48%. In the June 2026 quarter, revenue rose 10.40% to Rs 3,255.88 crore and net profit grew 22.12% to Rs 512.04 crore. The share price has gained 1461.53% over five years. Promoters hold 81.22%, which keeps ownership stable.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Fortis_Healthcare_Five-Year_Gain_of_24147\"><\/span><strong>Fortis Healthcare: Five-Year Gain of 241.47%<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Fortis Healthcare operates a chain of hospitals and diagnostic centres across India. It reported FY26 revenue of Rs 9,178.50 crore, up 16.93% year on year, and net profit of Rs 1,064.19 crore, up 31.48%. Net profit has compounded at 7.73% a year since FY22, while revenue has grown 12.43% a year. Operating margin was 22.41% in FY26. The debt-to-equity ratio is 0.35.<\/p>\n<p>In the June 2026 quarter, revenue rose 17.29% to Rs 2,559.50 crore and net profit grew 2.26% to Rs 272.80 crore. The share price has gained 241.47% over five years. Domestic institutions raised their holding from 29.79% in June 2025 to 32.23% in June 2026. The stock trades at a PE of 52.24 against an industry PE of 60.75, below the sector average.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Lal_PathLabs_Return_on_Equity_of_2013\"><\/span><strong>Dr Lal PathLabs: Return on Equity of 20.13%<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Dr Lal PathLabs is one of India&#8217;s leading diagnostic chains, running laboratories and collection centres across the country. It reported FY26 revenue of Rs 2,864.18 crore, up 12.11% year on year, and net profit of Rs 509.75 crore, up 3.56%. Net profit has compounded at 9.83% a year since FY22, while revenue has grown 7.56% a year. Operating margin was 30.90% in FY26. The debt-to-equity ratio is 0.08, which keeps interest costs low.<\/p>\n<p>The stock trades at a PE of 57.88 against an industry PE of 60.75, below the sector average, with a return on equity of 20.13%. In the June 2026 quarter, revenue rose 18.87% to Rs 829.60 crore and net profit grew 27.24% to Rs 170.50 crore. The share price is up 19.11% over the past year. Domestic institutions raised their holding from 17.91% in June 2025 to 21.59% in June 2026.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Steady_Revenue_Growth_Stocks_Financial_Comparison_on_Growth_and_Margins\"><\/span><strong>Steady Revenue Growth Stocks: Financial Comparison on Growth and Margins<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table compares scale and growth across these steady revenue growth stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Revenue Growth (YoY)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">4-Year Revenue CAGR<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">4-Year Net Profit CAGR<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Operating Margin (Latest Quarter)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Max Healthcare<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">8,536.07<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,442.41<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">18.82%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">20.42%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">24.26%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">27.00%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Mazagon Dock<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">14,145.71<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">2,421.88<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">12.77%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">23.18%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">44.01%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">25.82%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Fortis Healthcare<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">9,178.50<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,064.19<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">16.93%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">12.43%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">7.73%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">22.22%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Dr Lal PathLabs<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">2,864.18<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">509.75<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">12.11%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">7.56%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">9.83%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">35.03%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live data on these steady revenue growth stocks<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Institutional_Holding_in_Max_Healthcare_Mazagon_Dock_Fortis_Healthcare_and_Dr_Lal_PathLabs\"><\/span><strong>Institutional Holding in Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Institutional holding shows who is backing these steady revenue growth stocks alongside the promoter. The table uses the latest reported quarter for each. Max Healthcare has the deepest institutional backing, with FII and DII together holding 71.74% as of June 2026. Domestic institutions increased their holding over the past year in Max Healthcare (from 17.42% to 29.96%), Fortis Healthcare (from 29.79% to 32.23%) and Dr Lal PathLabs (from 17.91% to 21.59%).<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Promoter<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">FII<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">DII<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Public<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Quarter<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Max Healthcare<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">23.71%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">41.78%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">29.96%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">4.56%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">June 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Mazagon Dock<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">81.22%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1.72%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">5.01%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">12.04%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">June 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Fortis Healthcare<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">31.17%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">25.20%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">32.23%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">11.40%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">June 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Dr Lal PathLabs<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">53.19%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">17.36%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">21.59%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">7.86%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">June 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_Weigh_in_Steady_Revenue_Growth_Stocks\"><\/span><strong>Risks to Weigh in Steady Revenue Growth Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Being careful with steady revenue growth stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:<\/p>\n<ul>\n<li>Past growth may not repeat.<\/li>\n<li>Share prices can move sharply in either direction.<\/li>\n<li><strong>Valuation:<\/strong> A low PE can also reflect slower growth, so compare each PE with the growth rate instead of reading it alone.<\/li>\n<li><strong>Concentration:<\/strong> Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Choose_Between_Steady_Revenue_Growth_Stocks\"><\/span><strong>How to Choose Between Steady Revenue Growth Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Picking from steady revenue growth stocks comes down to four checks, applied in order.<\/p>\n<ol>\n<li>Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.<\/li>\n<li>Compare each PE with the industry PE (48.92 to 60.75) and ask whether the growth rate justifies any gap.<\/li>\n<li>Track net profit growth, the operating margin and the return on equity in every quarterly result.<\/li>\n<li>Stagger entries across quarters and review institutional holding every reporting season.<\/li>\n<\/ol>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs live prices.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among steady revenue growth stocks, Max Healthcare stands out for the largest market cap at Rs 85,241 crore, Mazagon Dock for the highest return on equity at 26.48%, Fortis Healthcare for 16.93% revenue growth in FY26 and Dr Lal PathLabs for the strongest latest-quarter profit growth at 27.24%. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing steady revenue growth stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Steady_Revenue_Growth_Stocks_to_Watch\"><\/span><strong>Frequently Asked Questions on Steady Revenue Growth Stocks to Watch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Which_are_the_best_steady_revenue_growth_stocks_to_watch_for_multibagger_potential\"><\/span><strong>Which are the best steady revenue growth stocks to watch for multibagger potential?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs are the 4 names this list highlights, with market caps of Rs 85,241 crore, Rs 82,736 crore, Rs 55,926 crore and Rs 31,620 crore respectively. Max Healthcare is notable for the largest market cap at Rs 85,241 crore. Mazagon Dock stands out for the highest return on equity at 26.48%. Fortis Healthcare offers 16.93% revenue growth in FY26. Dr Lal PathLabs brings the strongest latest-quarter profit growth at 27.24%. These are watchlist names for steady revenue growth stocks, not recommendations, so match each one to your own risk profile and time horizon.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Mazagon_Dock_a_good_stock_for_long-term_investors\"><\/span><strong>Is Mazagon Dock a good stock for long-term investors?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Mazagon Dock has a return on equity of 26.48%, a PE of 28.99 against an industry PE of 48.92 and a market cap of Rs 82,736 crore. Net profit has compounded at 44.01% a year since FY22, and FY26 revenue rose 12.77% while June 2026 quarter net profit grew 22.12%. Long-term returns in steady revenue growth stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Can_Max_Healthcare_become_a_multibagger_from_here\"><\/span><strong>Can Max Healthcare become a multibagger from here?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Max Healthcare has already gained 149.91% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in steady revenue growth stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 24.26% a year since FY22, and FY26 revenue rose 18.82%. At a PE of 58.50 against an industry PE of 60.75, valuation should be checked against that growth before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_cap_of_Max_Healthcare_Mazagon_Dock_Fortis_Healthcare_and_Dr_Lal_PathLabs\"><\/span><strong>What is the market cap of Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 26 October 2026, Max Healthcare has a market cap of Rs 85,241 crore, Mazagon Dock has a market cap of Rs 82,736 crore, Fortis Healthcare has a market cap of Rs 55,926 crore and Dr Lal PathLabs has a market cap of Rs 31,620 crore. All of them qualify as midcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on steady revenue growth stocks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_risks_of_investing_in_steady_revenue_growth_stocks\"><\/span><strong>What are the risks of investing in steady revenue growth stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Comparing each PE with growth gives a fuller picture than the PE alone.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Mazagon_Dock_trading_below_its_industry_PE\"><\/span><strong>Is Mazagon Dock trading below its industry PE?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Mazagon Dock trades at a PE of 28.99 against an industry PE of 48.92. A lower PE means investors pay less for each rupee of earnings, but it should be read with growth (net profit has compounded at 44.01% a year since FY22 and FY26 revenue rose 12.77%) and balance sheet strength before drawing a conclusion.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_much_do_institutions_hold_in_Max_Healthcare_Mazagon_Dock_Fortis_Healthcare_and_Dr_Lal_PathLabs\"><\/span><strong>How much do institutions hold in Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of the latest reported quarter, FII and DII together hold 71.74% of Max Healthcare (41.78% and 29.96%), 6.73% of Mazagon Dock (1.72% and 5.01%), 57.43% of Fortis Healthcare (25.20% and 32.23%) and 38.95% of Dr Lal PathLabs (17.36% and 21.59%). Rising institutional holding is a useful signal in steady revenue growth stocks, though it should be read with earnings trends rather than on its own.<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Which are the best steady revenue growth stocks to watch for multibagger potential?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs are the 4 names this list highlights, with market caps of Rs 85,241 crore, Rs 82,736 crore, Rs 55,926 crore and Rs 31,620 crore respectively. Max Healthcare is notable for the largest market cap at Rs 85,241 crore. Mazagon Dock stands out for the highest return on equity at 26.48%. Fortis Healthcare offers 16.93% revenue growth in FY26. Dr Lal PathLabs brings the strongest latest-quarter profit growth at 27.24%. These are watchlist names for steady revenue growth stocks, not recommendations, so match each one to your own risk profile and time horizon.\"}},{\"@type\":\"Question\",\"name\":\"Is Mazagon Dock a good stock for long-term investors?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Mazagon Dock has a return on equity of 26.48%, a PE of 28.99 against an industry PE of 48.92 and a market cap of Rs 82,736 crore. Net profit has compounded at 44.01% a year since FY22, and FY26 revenue rose 12.77% while June 2026 quarter net profit grew 22.12%. Long-term returns in steady revenue growth stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.\"}},{\"@type\":\"Question\",\"name\":\"Can Max Healthcare become a multibagger from here?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Max Healthcare has already gained 149.91% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in steady revenue growth stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 24.26% a year since FY22, and FY26 revenue rose 18.82%. At a PE of 58.50 against an industry PE of 60.75, valuation should be checked against that growth before investing.\"}},{\"@type\":\"Question\",\"name\":\"What is the market cap of Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 26 October 2026, Max Healthcare has a market cap of Rs 85,241 crore, Mazagon Dock has a market cap of Rs 82,736 crore, Fortis Healthcare has a market cap of Rs 55,926 crore and Dr Lal PathLabs has a market cap of Rs 31,620 crore. All of them qualify as midcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on steady revenue growth stocks.\"}},{\"@type\":\"Question\",\"name\":\"What are the risks of investing in steady revenue growth stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Comparing each PE with growth gives a fuller picture than the PE alone.\"}},{\"@type\":\"Question\",\"name\":\"Is Mazagon Dock trading below its industry PE?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Mazagon Dock trades at a PE of 28.99 against an industry PE of 48.92. A lower PE means investors pay less for each rupee of earnings, but it should be read with growth (net profit has compounded at 44.01% a year since FY22 and FY26 revenue rose 12.77%) and balance sheet strength before drawing a conclusion.\"}},{\"@type\":\"Question\",\"name\":\"How much do institutions hold in Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of the latest reported quarter, FII and DII together hold 71.74% of Max Healthcare (41.78% and 29.96%), 6.73% of Mazagon Dock (1.72% and 5.01%), 57.43% of Fortis Healthcare (25.20% and 32.23%) and 38.95% of Dr Lal PathLabs (17.36% and 21.59%). Rising institutional holding is a useful signal in steady revenue growth stocks, though it should be read with earnings trends rather than on its own.\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>4 midcap steady revenue growth stocks compared on market cap, PE, ROE, growth and institutional holding: Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs.<\/p>\n","protected":false},"author":33,"featured_media":327563,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[16367,16366],"class_list":["post-327564","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-steady-revenue-growth-sector","tag-steady-revenue-growth-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["327563"],"rank_math_title":["Steady Revenue Growth Stocks 2026: Max Healthcare, Mazagon Dock"],"rank_math_description":["Steady revenue growth stocks to watch for multibagger potential: Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs. Compare PE, ROE and growth."],"rank_math_focus_keyword":["steady revenue growth stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/4-midcap-steady-revenue-growth-stocks-to-watch-for-future-multibagger-potential.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/327564","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=327564"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/327564\/revisions"}],"predecessor-version":[{"id":327565,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/327564\/revisions\/327565"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/327563"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=327564"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=327564"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=327564"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}